CD8A and melanoma: Additionally, inhibiting CPT1A, a key enzyme in FAO, improves antigen-specific CD8+ T-cell responses and dendritic cell (DC)-mediated T-cell priming, enhancing anti-PD-1 therapy in BRAFV600E melanoma [236].